J Zheng1, X Guo, X Gao, H Liu, Y Tu, Y Zhang. 1. Department of Digestive Surgery, State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, 710033, People's Republic of China.
Abstract
AIM: To investigate clinical significance of retinoic acid-induced protein 3 (RAI3) in hepatocellular carcinoma (HCC). METHODS: Expression of RAI3 at both mRNA and protein levels in tumor, para-tumor and normal liver tissues was detected in 106 HCC patients by real-time quantitative RT-PCR, Western blot and immunohistochemistry. Then, the correlation of RAI3 expression with clinicopathological characteristics and survivals of HCC patients was analyzed. RESULTS: Our data first found that RAI3 mRNA and protein expression were both significantly higher in HCC than in para-tumor (both P < 0.001) and normal liver tissues (both P < 0.001). The correlation analysis showed a positive correlation between RAI3 mRNA level and RAI3 protein level in HCC tissues (r = 0.8, P < 0.001). Immunohistochemistry data also revealed that overexpression of RAI3 was present in 73.6 % (78/106) of HCC tissues. In addition, high RAI3 protein expression was correlated with advanced TNM stage (P = 0.001), high serum AFP (P = 0.008), vascular invasion (P = 0.01) and tumor recurrence (P = 0.008). Moreover, HCC patients with overexpression of RAI3 had significantly shorter overall (P = 0.01) and disease-free survival (P = 0.01). Furthermore, multivariate analysis showed that overexpression of RAI3 was an independent prognostic factor for both overall (P = 0.02) and disease-free survival (P = 0.03) in HCC. CONCLUSION: Our data for the first time provide a basis for the concept that overexpression of RAI3 may contribute to the malignant progression of HCC and predict poor prognosis for patients with this deadly disease after curative hepatectomy. RAI3 might be an important marker for tumor progression and prognosis, as well as a potential therapeutic target of HCC.
AIM: To investigate clinical significance of retinoic acid-induced protein 3 (RAI3) in hepatocellular carcinoma (HCC). METHODS: Expression of RAI3 at both mRNA and protein levels in tumor, para-tumor and normal liver tissues was detected in 106 HCC patients by real-time quantitative RT-PCR, Western blot and immunohistochemistry. Then, the correlation of RAI3 expression with clinicopathological characteristics and survivals of HCC patients was analyzed. RESULTS: Our data first found that RAI3 mRNA and protein expression were both significantly higher in HCC than in para-tumor (both P < 0.001) and normal liver tissues (both P < 0.001). The correlation analysis showed a positive correlation between RAI3 mRNA level and RAI3 protein level in HCC tissues (r = 0.8, P < 0.001). Immunohistochemistry data also revealed that overexpression of RAI3 was present in 73.6 % (78/106) of HCC tissues. In addition, high RAI3 protein expression was correlated with advanced TNM stage (P = 0.001), high serum AFP (P = 0.008), vascular invasion (P = 0.01) and tumor recurrence (P = 0.008). Moreover, HCC patients with overexpression of RAI3 had significantly shorter overall (P = 0.01) and disease-free survival (P = 0.01). Furthermore, multivariate analysis showed that overexpression of RAI3 was an independent prognostic factor for both overall (P = 0.02) and disease-free survival (P = 0.03) in HCC. CONCLUSION: Our data for the first time provide a basis for the concept that overexpression of RAI3 may contribute to the malignant progression of HCC and predict poor prognosis for patients with this deadly disease after curative hepatectomy. RAI3 might be an important marker for tumor progression and prognosis, as well as a potential therapeutic target of HCC.
Authors: M J Robbins; D Michalovich; J Hill; A R Calver; A D Medhurst; I Gloger; M Sims; D N Middlemiss; M N Pangalos Journal: Genomics Date: 2000-07-01 Impact factor: 5.736
Authors: Junya Fujimoto; Humam Kadara; Melinda M Garcia; Mohamed Kabbout; Carmen Behrens; Diane D Liu; J Jack Lee; Luisa M Solis; Edward S Kim; Neda Kalhor; Cesar Moran; Amir Sharafkhaneh; Reuben Lotan; Ignacio I Wistuba Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Nathaniel Melling; Kai Bachmann; Maximillian Bockhorn; Oliver Mann; Jakob Robert Izbicki; Katharina Grupp Journal: Int J Clin Exp Pathol Date: 2019-02-01
Authors: Matthew M Yeh; Raymond S Yeung; Smith Apisarnthanarax; Renuka Bhattacharya; Carlos Cuevas; William P Harris; Tony Lim Kiat Hon; Siddharth A Padia; James O Park; Kevin M Riggle; Sayed S Daoud Journal: World J Hepatol Date: 2015-06-18
Authors: Elisabeth Jahny; Hai Yang; Bin Liu; Beatrix Jahnke; Franziska Lademann; Thomas Knösel; Petra Rümmele; Robert Grützmann; Daniela E Aust; Christian Pilarsky; Axel Denz Journal: PLoS One Date: 2017-01-23 Impact factor: 3.240
Authors: H Zhou; A G Telonis; Y Jing; N L Xia; L Biederman; M Jimbo; F Blanco; E Londin; J R Brody; I Rigoutsos Journal: Cell Death Dis Date: 2016-07-14 Impact factor: 8.469
Authors: Daria R Bulanova; Yevhen A Akimov; Anne Rokka; Teemu D Laajala; Tero Aittokallio; Petri Kouvonen; Teijo Pellinen; Sergey G Kuznetsov Journal: Cell Adh Migr Date: 2017-02-06 Impact factor: 3.405
Authors: Esperanza Gonzalez; Mikel Azkargorta; Clara Garcia-Vallicrosa; Janire Prieto-Elordui; Felix Elortza; Sonia Blanco-Sampascual; Juan Manuel Falcon-Perez Journal: Int J Biol Sci Date: 2021-05-05 Impact factor: 6.580